Search
forLearn
5 / 801 resultslearn gentian
learn Synergen Complex ®
learn Follicusan
learn nonspecific group of Fibronectins
Research
5 / 1000+ results
research Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases
Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.
research Manifestaciones dermatológicas en pacientes oncológicos pediátricos en un hospital de tercer nivel de Honduras
Most pediatric cancer patients in the study developed skin problems, often due to their cancer treatment.
research PMON225 Androgen excess in pre-menopausal women due to Granulosa Cell tumor: A case report.
Removing the ovarian tumor improved the woman's hormonal symptoms.
research Síndrome dos ovários policísticos: correlação dos fenótipos com as manifestações metabólicas
Older age, obesity, hirsutism, and having children increase metabolic risk in women with PCOS.
research Rooster feathering, androgenic alopecia, and hormone-dependent tumor growth: What is in common?
Sex hormones affect hair and feather growth and may help manage alopecia and hormone-dependent cancers.
Community Join
5 / 1000+ resultscommunity Failed HT or expected result? 4505 grafts, Eugenix, New Delhi.
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Group Buy for MR antagonist finerenone
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.